NCT06024057尚未招募不适用
An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy (LX101) in Patients With Leber's Congenital Amaurosis (LCA)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine0 个研究点目标入组 3 人开始时间: 2023年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 3
- 主要终点
- Local and systemic safety assessment
研究概览
简要总结
To evaluate the scaling clinical trail of AAV2-RPE65 gene therapy agent (LX101) in patients with congenital amaurosis (LCA).
详细描述
This study evaluated the overall safety and initial efficacy of RPE65 mutant congenital amaurosis (RPE65-LCA) in subjects treated with a single, subretinal injection of LX101 (containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65) in the second eye 1 year after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants in the main study "Exploratory clinical study evaluating AAV2-RPE65 gene therapy formulation (LX101) in patients with congenital amaurosis (LCA) 2) Willingness to participate in the extended study, subject and/or their guardian signing a written informed consent and complying with a long-term follow-up protocol
排除标准
- •Have any of the following eye conditions:
- •Subjects with SAE in the "Exploratory clinical Study Evaluating AAV2-RPE65 gene therapy agent (LX101) in patients with congenital Amaurosis (LCA)
- •pre-existing eye conditions (such as glaucoma, cornea, or severe lens opacity) that the investigator determines may interfere with planned surgery or with interpretation of the study endpoint;
- •Screening subjects who had undergone any internal eye surgery in the six months prior to the visit;
- •Inability or unwillingness to meet the requirements of the study;
- •Have any of the following systemic conditions:
- •Known allergy to the drug planned for use in the study; 7) Have a history of surgical operations within 1 month before enrollment, and/or present unhealed wounds, ulcers, fractures, etc.; Present infectious disease requiring oral, intramuscular or intravenous administration; 8) Baseline laboratory values for complex systemic diseases or clinically significant abnormalities; 9) Complex systemic diseases include diseases in which the disease itself or the treatment of the disease can alter eye function. For example, the treatment of malignant tumors can affect central nervous system function (e.g., orbital radiation therapy; Leukemia with central/optic nerve involvement); 10) Subjects with a history of immune-damaging diseases due to the possibility of opportunistic infection (e.g., CMV retinitis); Subjects with diabetes or sickle cell disease will be excluded if they have any manifestations of advanced retinopathy, such as macular edema or proliferative changes. Subjects with juvenile rheumatoid arthritis have an increased risk of infection due to poor postoperative wound healing; 11) Participants who cannot discontinue Viagra (Sildenafil) or related compounds used to treat erectile dysfunction during the study period; 12) Subjects who cannot discontinue hydroxychloroquine, Chloroquine, meralide, or any related retinal toxic compound during the study; 13) Any other conditions in which the potential subject is not allowed to complete a follow-up examination during the study, and the investigator believes that there are conditions that make the potential subject unfit for the study.
- •Fertile subjects with any of the following conditions:
- •Those who do not use effective contraceptive measures; 15) Pregnant and lactating women.
研究组 & 干预措施
LX101
Experimental
干预措施: LX101 (Drug)
结局指标
主要结局
Local and systemic safety assessment
时间窗: 52（+4）weeks
Eye and non-eye adverse events
次要结局
未报告次要终点
研究者
Xiaodong Sun
Assessor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
相似试验
已完成
1 期
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)Leber Congenital AmaurosisNCT02781480MeiraGTx UK II Ltd15
进行中（未招募）
2 期
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)X-Linked Retinitis PigmentosaNCT06333249Beacon Therapeutics14
进行中（未招募）
1 期
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsX-Linked Retinitis PigmentosaNCT03316560Beacon Therapeutics29
已完成
1 期
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.Alzheimer DiseaseNCT00380302Sanofi162
已完成
1 期
Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 TreatmentSolid TumorsNCT01158079Alnylam Pharmaceuticals7